{"result": "(\"entity\"<|>CUSHING'S SYNDROME<|>EVENT<|>Cushing's syndrome is a hormonal disorder caused by prolonged exposure to high levels of cortisol, leading to various clinical manifestations and symptoms such as muscle weakness and skin changes.)\n##\n(\"entity\"<|>MITOTANE<|>ORGANIZATION<|>Mitotane is a medication used primarily in the treatment of adrenal carcinoma, inhibiting steroidogenesis and having various side effects.)\n##\n(\"entity\"<|>KETOCONAZOLE<|>ORGANIZATION<|>Ketoconazole is an antifungal medication that is also used to inhibit steroidogenesis in the treatment of Cushing's syndrome.)\n##\n(\"entity\"<|>METOPIRONE<|>ORGANIZATION<|>Metopirone is a medication that inhibits steroidogenesis and is used in the management of Cushing's syndrome.)\n##\n(\"entity\"<|>SSTR1<|>ORGANIZATION<|>SSTR1 is a subtype of somatostatin receptor that is targeted by certain medications for hormonal regulation.)\n##\n(\"entity\"<|>SSTR2<|>ORGANIZATION<|>SSTR2 is another subtype of somatostatin receptor involved in the treatment of hormonal disorders.)\n##\n(\"entity\"<|>SSTR3<|>ORGANIZATION<|>SSTR3 is a subtype of somatostatin receptor that plays a role in the pharmacological effects of somatostatin analogs.)\n##\n(\"entity\"<|>SSTR5<|>ORGANIZATION<|>SSTR5 is a subtype of somatostatin receptor that is targeted by medications to manage hormonal imbalances.)\n##\n(\"entity\"<|>Nieman LK<|>PERSON<|>Nieman LK is a researcher and author who has contributed to the literature on Cushing's syndrome and its treatment.)\n##\n(\"entity\"<|>ARLT W<|>PERSON<|>Arlt W is a researcher who has published work on adrenal cortex disorders, including Cushing's syndrome.)\n##\n(\"relationship\"<|>MITOTANE<|>CUSHING'S SYNDROME<|>Mitotane is used in the treatment of Cushing's syndrome, targeting the underlying hormonal imbalance<|>8)\n##\n(\"relationship\"<|>KETOCONAZOLE<|>CUSHING'S SYNDROME<|>Ketoconazole is used to inhibit steroidogenesis in patients with Cushing's syndrome<|>8)\n##\n(\"relationship\"<|>METOPIRONE<|>CUSHING'S SYNDROME<|>Metopirone is utilized in the management of Cushing's syndrome by inhibiting steroid hormone production<|>8)\n##\n(\"relationship\"<|>SSTR1<|>CUSHING'S SYNDROME<|>SSTR1 is a target for medications that regulate hormonal levels in conditions like Cushing's syndrome<|>6)\n##\n(\"relationship\"<|>SSTR2<|>CUSHING'S SYNDROME<|>SSTR2 is involved in the pharmacological treatment of hormonal disorders, including Cushing's syndrome<|>6)\n##\n(\"relationship\"<|>SSTR3<|>CUSHING'S SYNDROME<|>SSTR3 is a receptor subtype that is targeted in the treatment of Cushing's syndrome<|>6)\n##\n(\"relationship\"<|>SSTR5<|>CUSHING'S SYNDROME<|>SSTR5 is a receptor that is involved in the management of hormonal imbalances in Cushing's syndrome<|>6)\n##\n(\"relationship\"<|>NIEMAN LK<|>CUSHING'S SYNDROME<|>Nieman LK has authored significant literature on the epidemiology and treatment of Cushing's syndrome<|>7)\n##\n(\"relationship\"<|>ARLT W<|>CUSHING'S SYNDROME<|>Arlt W has contributed to the understanding and treatment guidelines for Cushing's syndrome<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: oides. A continuación, siempre debe ser excluida la causa yatrógena por admi-          las siguientes enzimas es estimulada por la sustancia que produce el síndrome de\n               nistración exógena de glucocorticoides.                                                           Cushing?\n               El cuadro clínico es muy variable y depende de diferentes factores como la edad, el sexo, la      A. Colesterol desmolasa.\n               intensidad del hipercortisolismo, el tiempo de evolución y, hasta cierto punto, la causa. Los\n               síntomas más específicos de síndrome de Cushing son los derivados de los efectos catabóli-        B. 11-β-hidroxilasa.\n               cos del cortisol: atrofia cutánea, equimosis, debilidad muscular y osteoporosis. Los pacien-      C. 21-β-hidroxilasa.\n               tes con enfermedad de Cushing o adenomas suprarrenales suelen desarrollar el síndrome de          D.  β-hidroxiesteroide deshidrogenasa.\n               manera lenta y progresiva; sin embargo, los pacientes con síndrome de Cushing por secreción\n\n\n\n258                                                                                                                                                                                                                                            259\n---\n                                                                                                                                                                                                                                SUPRARRENALES                                           5\n\n\n\n        COMENTARIO                                                                                                                                 los edemas, aunque infrecuentes, pueden obligar a suspender el tratamiento. Las náuseas\n        La secreción excesiva de ACTH                     actúa sobre la secreción de las hormonas esteroideas de                                  y vómitos son reacciones adversas del medicamento frecuentes.\n        una manera inmediata al estimular la liberación de colesterol a las mitocondrias, donde se                                                 El mitotano, además de inhibir varias enzimas de la esteroidogénesis, tiene efectos adre-\n        encuentra la enzima             P450scc        o  colesterol      desmolasa que            cataliza     el  primer paso         de la      nolíticos y se utiliza, fundamentalmente, en el tratamiento del carcinoma suprarrenal. Su\n        esteroidogénesis, que es la escisión de la cadena lateral del colesterol para transformar el                                               comienzo de acción es lento, por lo que debe asociarse, inicialmente, a otros inhibidores\n        colesterol en pregnenolona.                                                                                                                de la   esteroidogénesis (ketoconazol o metopirona). Sus                            efectos secundarios digestivos y\n                                                                                                                                                   neurológicos son frecuentes y pueden obligar a suspender el tratamiento.\n        Referencias:\n        • Arlt W. Trastornos de la corteza suprarrenal. En: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscazo J, eds. Harrison         La   pasireotida       es   un   nuevo      análogo      de   somatostatina          con    afinidad     por    SSTR1,      SSTR2,\n          Principios de Medicina Interna. 19.ª edición en español. México DF: Mc Graw Hill; 2016. p. 2309-29.                                      SSTR3 y SSTR5. Un estudio multicéntrico aleatorizado normalizó los niveles de cortisol\n        • Estrada J, Abad A, Aller J. Síndrome de Cushing. Manual de Endocrinología y Nutrición. Disponible en: https://manual.seen.es (última\n          modificación: 25 de noviembre de 2015).                                                                                                  libre  urinario hasta en un 26% de los casos. Sus efectos adversos son                                   similares a      los otros\n        • Nieman LK. Epidemiology and clinical manifestations of Cushing’s syndrome. UpToDate. Waltham, MA: UpToDate Inc. https://www.\n          uptodate.com. Literature review current through: Apr. 2019.                                                                              análogos de somatostatina, excepto la                       hiperglucemia, mucho más frecuente con la pasi-\n        • Nieman LK. Establishing the diagnosis of Cushing’s syndrome. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com.              reotida por su capacidad para inhibir la secreción de insulina.\n          Literature review current through: Apr. 2019.\n        • Nieman LK. Overview of the treatment of Cushing’s syndrome. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com.               Referencias:\n          Literature review current through: Apr. 2019.\n        • Nieman LK, Biller BMK, Findiling JW, Murad MH, Newel-Price J, Savage MO, et al. Treatment of Cushing’s syndrome: an Endocrine            • Arlt W. Trastornos de la corteza suprarrenal. En: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscazo J, eds. Harrison\n          Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100:2807-31.                                                            Principios de Medicina Interna. 19.ª edición en español. México DF: Mc Graw Hill; 2016. p. 2309-29.\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}